Heart Failure with Preserved Ejection Fraction: Management Guidelines (From Heart Failure Association of India, Endorsed by Association of Physicians of India).
Journal
The Journal of the Association of Physicians of India
ISSN: 0004-5772
Titre abrégé: J Assoc Physicians India
Pays: India
ID NLM: 7505585
Informations de publication
Date de publication:
Aug 2022
Aug 2022
Historique:
entrez:
9
9
2022
pubmed:
10
9
2022
medline:
14
9
2022
Statut:
ppublish
Résumé
Heart failure with preserved ejection fraction (HFpEF) accounts for 15-20% of patients with heart failure (HF) in India. Diagnosis is by clinical features supported by biomarkers and echocardiography. Lifestyle modifications, control of risk factors to optimum levels, and treatment of comorbidities are essential in the management of HFpEF. Spironolactone and sacubitril-valsartan [angiotensin receptor neprilysin inhibitor (ARNI)] are beneficial in subsets of HFpEF, especially with lower range of ejection fraction (EF). Sodium-glucose co-transporter-2 inhibitors (SGLT2i)-empagliflozin and dapagliflozin and probably sotagliflozin are the only currently available drugs which have shown benefits in HFpEF, mostly by reducing hospitalizations. The benefit of SGLT2i is evident in both diabetic and nondiabetic subsets.
Identifiants
pubmed: 36082729
doi: 10.5005/japi-11001-0077
doi:
Substances chimiques
Aminobutyrates
0
Angiotensin Receptor Antagonists
0
Biphenyl Compounds
0
Drug Combinations
0
Sodium-Glucose Transporter 2 Inhibitors
0
Tetrazoles
0
sacubitril
17ERJ0MKGI
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
11-12Informations de copyright
© Journal of the Association of Physicians of India 2011.